Replies to post #329 on Idenix Pharmaceuticals (IDIX)

[go seek]

you are not alone in seeking this info... it has not been provided (that is recent data post April 06)

If IDIX and NVS can mitigate the GI effects of higher doses of NM283 w/ something "creative"... the word "creative" used in past CC... the treatment refractory area may be a more fertile area for NM283 than treatment naive.

progress to date on the refractory side is a (?) @ present.

[gofishmarko]

Here are some results from DDW '06 :

http://www.natap.org/2006/DDW/DDW_19.htm

We're all anxiously awaiting the announcement of the game plan for nonresponders. The pending ribavirin interaction study probably has something to do with the delay.